uniQure price target lowered to $53 from $76 at Chardan

Chardan analyst Daniil Gataulin lowered the firm’s price target on uniQure (QURE) to $53 from $76 and keeps a Buy rating on the shares after the company announced that it has assessed that the FDA no longer agrees that data from uniQure’s ongoing Phase 1/2 studies of AMT-130 compared to external control will be sufficient to support a BLA filing for its Huntington’s disease gene therapy. The company had previously guided toward a BLA submission in Q1 of 2026, but that timeline is “now unlikely,” says the analyst, who is pushing back expectations for the potential launch of AMT-130 to 2028 given uncertainty following today’s update.